Abstract
Nanoparticle albumin-bound (nab) paclitaxel is an active agent for non–small cell lung cancer (NSCLC). Nab-paclitaxel proved to be noninferior to docetaxel with regard to overall survival (OS), having showcased improved progression-free survival (PFS) and overall response rate (ORR) in patients with previously treated advanced NSCLC, according to findings from the phase III trial in Japan (J-AXEL study, 2021). In chemotherapy for advanced NSCLC, it is expected that administration of the optimal dose for as long as possible will lead to improvement of prognosis rather than administration of the maximum tolerated dose for a short period of time.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call